Scarica l'app Stockscreener
47.03
0.32%
-0.15
Dopo l'orario di chiusura:
47.16
0.13
+0.28%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$47.18
Aprire:
$47.08
Volume 24 ore:
5.35M
Relative Volume:
1.49
Capitalizzazione di mercato:
$94.23B
Reddito:
$43.93B
Utile/perdita netta:
$8.53B
Rapporto P/E:
12.30
EPS:
3.824
Flusso di cassa netto:
$5.74B
1 W Prestazione:
-4.49%
1M Prestazione:
-6.76%
6M Prestazione:
-17.04%
1 anno Prestazione:
+7.64%
Intervallo 1D:
$46.84
$47.16
Intervallo di 1 settimana:
$46.84
$49.82
Portata 52W:
$42.84
$61.70
Gsk Plc Adr Stock (GSK) Company Profile
Nome
Gsk Plc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare GSK vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
47.03 | 98.65B | 43.93B | 8.53B | 5.74B | 3.824 |
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 623.34B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 459.33B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.30 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.00 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-27 | Iniziato | Citigroup | Neutral |
| 2026-01-06 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-11-25 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-06-03 | Downgrade | Berenberg | Buy → Hold |
| 2025-04-15 | Iniziato | Exane BNP Paribas | Neutral |
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Downgrade | Jefferies | Buy → Hold |
| 2024-10-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-07-08 | Downgrade | UBS | Buy → Neutral |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-03-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-02-13 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-01-23 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Ripresa | UBS | Buy |
| 2024-01-03 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-03-17 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Ripresa | Goldman | Buy |
| 2023-01-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Downgrade | UBS | Neutral → Sell |
| 2022-09-15 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Ripresa | Citigroup | Neutral |
| 2022-02-11 | Downgrade | DZ Bank | Buy → Hold |
| 2021-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Downgrade | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Iniziato | Deutsche Bank | Hold |
| 2020-11-02 | Aggiornamento | Liberum | Hold → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-02-12 | Downgrade | Shore Capital | Hold → Sell |
| 2020-01-16 | Downgrade | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Iniziato | SVB Leerink | Outperform |
| 2019-11-21 | Aggiornamento | UBS | Neutral → Buy |
| 2019-10-11 | Aggiornamento | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Ripresa | Citigroup | Neutral |
| 2019-09-03 | Aggiornamento | Societe Generale | Sell → Buy |
| 2019-08-13 | Ripresa | JP Morgan | Neutral |
| 2019-06-17 | Ripresa | Morgan Stanley | Underweight |
| 2019-03-08 | Downgrade | Shore Capital | Buy → Hold |
| 2019-02-22 | Downgrade | UBS | Buy → Neutral |
| 2019-01-14 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Ripresa | Jefferies | Buy |
| 2018-10-09 | Iniziato | Guggenheim | Neutral |
| 2018-08-30 | Downgrade | Liberum | Buy → Hold |
| 2018-04-04 | Aggiornamento | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Aggiornamento | Kepler | Reduce → Hold |
Mostra tutto
Gsk Plc Adr Borsa (GSK) Ultime notizie
Hatteras Venture Partners Names Sir Andrew Witty as Chairman and Ned Sharpless, M.D., as Managing Director of Hatteras Discovery Innovation, Expanding Proven Investment Strategies - GlobeNewswire Inc.
GSK plc (GSK) Stock Price, News, Quote & History - Yahoo! Finance Canada
GSK Stock Quote Price and Forecast - CNN
Key facts: GSK plc Sponsored ADR Upgraded; Acquires Chimagen T‑cell Asset - TradingView
GSK plc (GSK) stock price, news, quote and history - Yahoo Finance Australia
Zacks Investment Research - גלובס
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit? - TradingView
GSK stock holds steady as investors weigh recent earnings and dividend - ad-hoc-news.de
Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease? - sahmcapital.com
Resilient GSK stock holds firm as FDA and Japan clear key drugs - ad-hoc-news.de
Resilient GSK stock steadies after recent earnings beat and sector scrutiny - ad-hoc-news.de
ETFs Investing in GSK plc Sponsored ADR Stocks - TradingView
GSK Set up for Steady Long-Term Growth As Portfolio and Pipeline Develop - Morningstar
Inside ARMH, STHH and ASMH: Three Semiconductor ADRhedged™ ETFs, and What the Currency Hedge Actually Added - TipRanks
Trump Administration Reportedly Weighs Executive Order on Autism and Vaccines Days After RFK Jr. Hinted At 'Certain Interventions' - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Weekly Recap: £1.9B savings target and Artemis-011 hits Phase III goal - TradingView
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan - TradingView
GSK reports $11.28 billion second quarter 2026 revenue - grafa.com
GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals - Sahm
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Revenue Breakdown – BCBA:GSK - TradingView
Bank of New York Mellon Corp Reduces Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK: Glaxosmithkline plcADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule - Sahm
Free cash flow of GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs – BCBA:GSK.CI - TradingView
Dorsey Wright & Associates Takes Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK ends camlipixant programme after CALM-2 miss - grafa.com
Disappointing Data Prompts GSK to Drop Cough Drug Development - Sahm
GSKH ETF Profile: Dividends, Returns (AMEX:GSKH) - TradingView
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer - TradingView
GSK reports Jemperli rectal cancer trial results - grafa.com
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - Sahm
As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus - Morningstar
Price to earnings forward of GSK plc Sponsored ADR – MUN:GS70 - TradingView
GSKGSK Plc ADR Latest SEC Filings - Finviz
GS70 Forecast — Price Target — Prediction for 2027 - TradingView
Shareholder in GSK (NYSE: GSK) trims voting stake to 4.96% - Stock Titan
GSK to strengthen oncology pipeline with $10.6B Nuvalent buyout - MSN
Price to earnings forward of GSK plc Sponsored ADR – LS:A3DMHS - TradingView
A3DMHS Forecast — Price Target — Prediction for 2027 - TradingView
GSK (GSK) reports major holder crossing 5% voting rights threshold - Stock Titan
Gsk Plc Adr Azioni (GSK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):